ID    AVR/I/SSAP1
ET    Clinical
PN    Melittin
PL    26 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bee venom
SO    Apis mellifera
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-9 (clinical isolate collected from burn wound infections)
IC    MIC = 2 microM
TH    High toxicity to erythrocytes and other human cells
XR    PubMed: 34087287
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 3QRX_B
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1BH1_A
XR    UniProt: P68407
XR    UniProt: P01501
XR    UniProt: Q8LW54
XR    DrugBank: DB10955
XX
SQ    SEQUENCE  
      GIGAVLKVLT TGLPALISWI KRKRQQ 
//


ID    AVR/I/SSAP2
ET    Clinical
PN    Magainin-2
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Xenopus laevis
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-8 (clinical specimen from the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 16797106
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2LSA_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2MAG_A
XR    UniProt: C0HKN6
XR    UniProt: P11006
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GIGKFLHSAK KFGKAFVGEI MNS 
//


ID    AVR/I/SSAP3
ET    Clinical
PN    Temporin-CPa
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lithobates capito
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC => 25 microM
TH    Hemolysis of human erythrocytes at high concentrations
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IPPFIKKVLT TVF 
//


ID    AVR/I/SSAP4
ET    Clinical
PN    Temporin-CPb
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lithobates capito
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC = 12.5 microM
TH    Hemolysis of human erythrocytes at high concentrations
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLPIVGRLIS GIL 
//


ID    AVR/I/SSAP5
ET    Clinical
PN    Temporin-1Ga
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana grylio
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC = 6.2 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      SILPTIVSFL SKVF 
//


ID    AVR/I/SSAP6
ET    Clinical
PN    Temporin-1OLa
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana okaloosae
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC = 3.1 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLPFLKSILG KIL 
//


ID    AVR/I/SSAP7
ET    Clinical
PN    Temporin-1SPa
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana septentrionalis
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC = 12.5 microM
TH    Moderate hemolytic effect on human erythrocytes
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLSAITSILG KIL 
//


ID    AVR/I/SSAP8
ET    Clinical
PN    Temporin-1Oc
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana ornativentris
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA-28 (clinical strain)
IC    MIC = 1.6 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 29842923
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLPLLASLFR LF 
//


ID    AVR/I/SSAP9
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 4 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP10
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-7 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP11
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-8 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP12
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-9 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 4 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP13
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-10 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 4 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP14
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-11 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP15
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-12 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 4 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP16
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-4 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 1 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP17
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-5 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 1 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP18
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 1 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP19
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP20
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-7 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP21
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-8 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP22
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-9 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP23
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-10 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP24
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-11 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP25
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-12 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP26
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-4 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP27
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-5 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP28
ET    Clinical
PN    DIK-8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-6 (clinical isolate of multi-drug resistant S. aureus were provided by Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA) program supported under NIAID/NIH Contract # HHSN272200700055C)
IC    MIC = 8 microM
TH    Not available
XR    PubMed: 27405275
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP29
ET    Clinical
PN    Fl-PRPRPL-5
PL    10 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 5 (clinical isolate)
IC    MIC = 16 microM, MBC = 16 microM
TH    Not available
XR    PubMed: 26543355
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLPRPRPLPQ 
//


ID    AVR/I/SSAP30
ET    Clinical
PN    Mersacidin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus sp. strain HIL Y-85, 54728
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA strain SA137/93A (clinical isolate)
IC    MIC = 35 microG/ML
TH    Not available
XR    PubMed: 18947397
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      A-Abu-I-Ab u-L-P-C-G- G-G-V-A-Ab u-L-Abu-Dh a-E-A-I 
//


ID    AVR/I/SSAP31
ET    Clinical
PN    Mersacidin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus sp. strain HIL Y-85, 54729
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA strain SA137/ 93G (clinical isolate)
IC    MIC = 30 microG/ML
TH    Not available
XR    PubMed: 18947397
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      A-Abu-I-Ab u-L-P-C-G- G-G-V-A-Ab u-L-Abu-Dh a-E-A-I 
//


ID    AVR/I/SSAP32
ET    Clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.5 microM
TH    Not available
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP33
ET    Clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.7 microM
TH    Not available
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP34
ET    Clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.9 microM
TH    Not available
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP35
ET    Clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 2.8 microM
TH    Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP36
ET    Clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 1.9 microM
TH    Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP37
ET    Clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 2.8 microM
TH    Lipopeptide 2 showed no cytotoxic activity at concentrations up to 15microM against HEK293 and HepG2 cell lines and did not induce significant hemolysis even at 100microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP38
ET    Clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP39
ET    Clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP40
ET    Clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 3 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP41
ET    Clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP42
ET    Clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP43
ET    Clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 30 microM
TH    Lipopeptides 4 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP44
ET    Clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.2 microM
TH    Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP45
ET    Clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.1 microM
TH    Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP46
ET    Clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 0.1 microM
TH    Lipopeptides 5 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP47
ET    Clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 4) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 2.8 microM
TH    Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP48
ET    Clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 1) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 1.9 microM
TH    Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP49
ET    Clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (NARSA VRS 10) (clinical isolate from the University of Queensland Centre for Clinical Research (UQCCR))
IC    MIC = 1.9 microM
TH    Lipopeptides 6 did not exhibit cytotoxic activity at concentrations up to 15 microM against the tested mammalian cell lines (HEK293 and HepG2) and did not induce significant hemolytic effects even at high concentrations of 100 microM.
XR    PubMed: 27048775
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP50
ET    Clinical
PN    MP196
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    SG511 (VISA) (clinical isolate provided by Hans-Georg Sahl, University of Bonn, Germany, and Keiichi Hiramatsu, Juntendo University, Bunkyo, Japan)
IC    MIC = 16 microG/ML
TH    MP196 was only slightly hemolytic at high concentrations and not significantly cytotoxic to various human and animal cell lines, but it caused erythrocyte shrinking at 250microg/mL and severe morphological changes and lysis at 500microg/mL in murine red blood cells. In mice, intravenous doses of MP196 led to acute toxicity, including symptoms like excitement, indisposition, hind leg paralysis, and eventual death at higher concentrations.
XR    PubMed: 27617260
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWRWRW-NH2 
//


ID    AVR/I/SSAP51
ET    Clinical
PN    MP196
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate provided by Hans-Georg Sahl, University of Bonn, Germany, and Keiichi Hiramatsu, Juntendo University, Bunkyo, Japan)
IC    MIC = 64 microG/ML
TH    MP196 was only slightly hemolytic at high concentrations and not significantly cytotoxic to various human and animal cell lines, but it caused erythrocyte shrinking at 250microg/mL and severe morphological changes and lysis at 500microg/mL in murine red blood cells. In mice, intravenous doses of MP196 led to acute toxicity, including symptoms like excitement, indisposition, hind leg paralysis, and eventual death at higher concentrations.
XR    PubMed: 27617260
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWRWRW-NH2 
//


ID    AVR/I/SSAP52
ET    Clinical
PN    Cecropin A
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Hyalophora cecropi
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA (the VISA strain was isolated from a clinical specimen submitted for routine bacteriological investigation to the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)
IC    FIC = 0.312
TH    Cecropin A exhibits low cytotoxicity towards mammalian cells at certain concentrations
XR    PubMed: 16797106
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2LSA_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2MAG_A
XR    UniProt: C0HKN6
XR    UniProt: P11006
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GIGKFLHSAK KFGKAFVGEI MNS 
//


ID    AVR/I/SSAP53
ET    Clinical
PN    Magainin-2
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Xenopus laevis
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA (the VISA strain was isolated from a clinical specimen submitted for routine bacteriological investigation to the Institute of Infectious Diseases and Public Health, Polytechnic University of Marche, Ancona, Italy)
IC    FIC = 0.458
TH    Magainin II exhibits low cytotoxicity towards mammalian cells, is non-hemolytic, and selectively disrupts bacterial membranes, demonstrating a favorable safety profile and broad antimicrobial activity.
XR    PubMed: 16797106
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2LSA_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2MAG_A
XR    UniProt: C0HKN6
XR    UniProt: P11006
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GIGKFLHSAK KFGKAFVGEI MNS 
//


ID    AVR/I/SSAP54
ET    Clinical
PN    Smp24
PL    24 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA MU50 (clinical isolate from Sheffield Hallam University)
IC    MIC = 32 microG/ML
TH    Smp24, a broad-spectrum antimicrobial peptide from Scorpio maurus palmatus venom, disrupts membranes and causes hemolysis, unlike the non-hemolytic Smp43, with its hemolytic and cytotoxic effects influenced by modifications like truncation and the addition of a Gly-Val-Gly hinge.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLP--SLFG GG-KKDS 
//


ID    AVR/I/SSAP55
ET    Clinical
PN    Smp24
PL    24 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA KM126 (clinical isolate from Sheffield Hallam University)
IC    MIC = 64 microG/ML
TH    Smp24, a broad-spectrum antimicrobial peptide from Scorpio maurus palmatus venom, disrupts membranes and causes hemolysis, unlike the non-hemolytic Smp43, with its hemolytic and cytotoxic effects influenced by modifications like truncation and the addition of a Gly-Val-Gly hinge.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLP--SLFG GG-KKDS 
//


ID    AVR/I/SSAP56
ET    Clinical
PN    Smp24GVG
PL    26 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA MU50 (clinical isolate from Sheffield Hallam University)
IC    MIC = 32 microG/ML
TH    The addition of a Gly-Val-Gly hinge to Smp24, resulting in Smp24GVG, did not alter its hemolytic activity or significantly change its cytotoxicity in HepG2 cells compared to the parent peptide.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLGVGSLFG GG-KKDS 
//


ID    AVR/I/SSAP57
ET    Clinical
PN    Smp24GVG
PL    26 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA KM126 (clinical isolate from Sheffield Hallam University)
IC    MIC = 64 microG/ML
TH    The addition of a Gly-Val-Gly hinge to Smp24, resulting in Smp24GVG, did not alter its hemolytic activity or significantly change its cytotoxicity in HepG2 cells compared to the parent peptide.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLGVGSLFG GG-KKDS 
//


ID    AVR/I/SSAP58
ET    Clinical
PN    Smp24T
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA MU50 (clinical isolate from Sheffield Hallam University)
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLL--PSLFG G 
//


ID    AVR/I/SSAP59
ET    Clinical
PN    Smp24T
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA KM126 (clinical isolate from Sheffield Hallam University)
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLL--PSLFG G 
//


ID    AVR/I/SSAP60
ET    Clinical
PN    Smp43
PL    43 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA MU50 (clinical isolate from Sheffield Hallam University)
IC    MIC = 32 microG/ML
TH    Unlike the haemolytic Smp24, Smp43 was non-haemolytic but exhibited concentration-dependent cytotoxicity in HepG2 cells, as indicated by ATP release.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      G-VWDWIKKT AGKIWNSEPV KALKSQALNA AKNFVAEKIG ATPS 
//


ID    AVR/I/SSAP61
ET    Clinical
PN    Smp43
PL    43 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA KM126 (clinical isolate from Sheffield Hallam University)
IC    MIC = 64 microG/ML
TH    Unlike the haemolytic Smp24, Smp43 was non-haemolytic but exhibited concentration-dependent cytotoxicity in HepG2 cells, as indicated by ATP release.
XR    PubMed: 27019370
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      G-VWDWIKKT AGKIWNSEPV KALKSQALNA AKNFVAEKIG ATPS 
//


ID    AVR/I/SSAP62
ET    Clinical
PN    Melittin
PL    26 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bee venom
SO    Apis mellifera
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA (clinical isolate from burn-associated infections at Laboratory of Shahid Motahari Hospital)
IC    MBC = 0.125-2 microG/ML
TH    Melittin was evaluated for dermal toxicity on burned and normal skin at various time points (2, 24, 48, and 72 hours), showing no morphological changes in both test and normal groups. An in vivo hemolysis assay in mice revealed no hemolysis in the test groups compared to controls. These results indicate that melittin at the tested concentration did not cause dermal toxicity or hemolysis.
XR    PubMed: 34087287
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 3QRX_B
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1BH1_A
XR    UniProt: P68407
XR    UniProt: P01501
XR    UniProt: Q8LW55
XR    DrugBank: DB10955
XX
SQ    SEQUENCE  
      GIGAVLKVLT TGLPALISWI KRKRQQ 
//


ID    AVR/I/SSAP63
ET    Clinical
PN    Persulcatusin(IP)
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    Midgut
SO    Ixodes persulcatus 
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 8 microG/ML 1 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQGA CHRHCRSIGR RGGYCAGLFK QTCTCYSR 
//


ID    AVR/I/SSAP64
ET    Clinical
PN    IR
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes ricinus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGYYCPFFQD KCHRHCR SF GRKAGYCGGF LKKTCICV 
//


ID    AVR/I/SSAP65
ET    Clinical
PN    HAE
PL    36 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Haemaphysalis longicornis
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GCPLNQGACH NHCRSIGRRG GYCAGIIKQT CTCYRK 
//


ID    AVR/I/SSAP66
ET    Clinical
PN    OMBAC
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ornithodoros moubata
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQ Y ECHAHCSGVP GYKGGYCKGL FKQTCNCY 
//


ID    AVR/I/SSAP67
ET    Clinical
PN    BMAP28
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bovine Myeloid 
SO    Bos taurus
TX    Animalia (Cow)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGLRSLGKKI LRAWKKYGPI IVPIIRI 
//


ID    AVR/I/SSAP68
ET    Clinical
PN    Persulcatusin(IP)
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    Midgut
SO    Ixodes persulcatus 
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRS1 (VRSA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 2 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQGA CHRHCRSIGR RGGYCAGLFK QTCTCYSR 
//


ID    AVR/I/SSAP69
ET    Clinical
PN    IR
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes ricinus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRS1 (VRSA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGYYCPFFQD KCHRHCR SF GRKAGYCGGF LKKTCICV 
//


ID    AVR/I/SSAP70
ET    Clinical
PN    HAE
PL    36 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Haemaphysalis longicornis
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRS1 (VRSA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GCPLNQGACH NHCRSIGRRG GYCAGIIKQT CTCYRK 
//


ID    AVR/I/SSAP71
ET    Clinical
PN    OMBAC
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ornithodoros moubata
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRS1 (VRSA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 8 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQ Y ECHAHCSGVP GYKGGYCKGL FKQTCNCY 
//


ID    AVR/I/SSAP72
ET    Clinical
PN    BMAP28
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bovine Myeloid 
SO    Bos taurus
TX    Animalia (Cow)
VL    Experimentally validated
XX
TO    VRS1 (VRSA) (clinical isolate stored at TS
TO    Nissui, Tokyo, Japan)
IC    MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGLRSLGKKI LRAWKKYGPI IVPIIRI 
//


ID    AVR/I/SSAP73
ET    Clinical
PN    Daptomycin
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptomyces roseosporus
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA HMC3 (clinical strain isolated at the Hershey Medical Center)
IC    MIC = 0.5 mg/L
TH    Not available
XR    PubMed: 14563898
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00080
XX
SQ    SEQUENCE  
      Thr-D-Asn- Glu-Tyr-As n-Pro-L-As n-Gly-L-Th r-L-Ser-D- Asn-Gly-L- 
      Thr-L-Thr- L-Cys-L-Th r 
//


ID    AVR/I/SSAP74
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS19) (clinical isolate)
IC    EC50 = 1 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP75
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS37) (clinical isolate)
IC    EC50 = 1 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP76
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS1) (clinical isolate)
IC    EC50 = 1 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP77
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS4) (clinical isolate)
IC    EC50 = 4 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP78
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS5) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP79
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS10) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP80
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS11a) (clinical isolate)
IC    EC50 = 4 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP81
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS11b) (clinical isolate)
IC    EC50 = 4 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP82
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS12) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP83
ET    Clinical
PN    WR12
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS13) (clinical isolate)
IC    EC50 = 4 microM
TH    The MTS assay on HaCat cells revealed that WR12 have EC50 value of 128microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR 
//


ID    AVR/I/SSAP84
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS19) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP85
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS37) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP86
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA (NRS1) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP87
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS4) (clinical isolate)
IC    EC50 = 8 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP88
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS5) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP89
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS10) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP90
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS11a) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP91
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS11b) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP92
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS12) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP93
ET    Clinical
PN    D-IK8
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA (VRS13) (clinical isolate)
IC    EC50 = 16 microM
TH    The MTS assay on HaCat cells revealed that D-IK8 have EC50 value of > 256microM, indicating low toxicity to mammalian cells relative to their antimicrobial potency, which suggests a favorable drug safety profile and selective action against bacterial membranes.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IRIKIRIK 
//


ID    AVR/I/SSAP94
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VISA (NRS19) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP95
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VISA (NRS37) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP96
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VISA (NRS1) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP97
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS4) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP98
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS5) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP99
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS10) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP100
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS11a) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP101
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS11b) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP102
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS12) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP103
ET    Clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Human skin
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA (VRS13) (clinical isolate)
IC    EC50 = 128 microM
TH    Low toxicity and hemolytic activity.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP104
ET    Clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VRS1(VRSA) (clinical isolate)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP105
ET    Clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50(VISA) (clinical isolate)
IC    MIC = 16 microM
TH    Not available
XR    PubMed: 27531221
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP106
ET    Clinical
PN    Ramoplanin
PL    7 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    glycolipodepsipeptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA HMC3 (clinical strain isolated at the Hershey Medical Center)
IC    MIC = 0.125-0.5 mg/L
TH    Not available
XR    PubMed: 14563898
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB04952
XX
SQ    SEQUENCE  
      Ac-D-Tyr-D -Tyr-D-4Cl -Phe-L-Ser -D-Hpg-D-O rn-D-Leu-D -Arg-D-Asn 
      -NH2 
//


ID    AVR/I/SSAP107
ET    Clinical
PN    Cryptdin-4 (Crp-4)
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    a-defensin
SO    Mouse
TX    Animalia (Mouse)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1TV0_A
XR    UniProt: P28311
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GLLCYCRKGH CKRGERVRGT C---GIRFLY CCPRR 
//


ID    AVR/I/SSAP108
ET    Clinical
PN    Cryptdin-4 (Crp-4)
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    a-defensin
SO    Mouse
TX    Animalia (Mouse)
VL    Experimentally validated
XX
TO    Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1TV0_A
XR    UniProt: P28311
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GLLCYCRKGH CKRGERVRGT C---GIRFLY CCPRR 
//


ID    AVR/I/SSAP109
ET    Clinical
PN    Cryptdin-4 (Crp-4)
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    a-defensin
SO    Mouse
TX    Animalia (Mouse)
VL    Experimentally validated
XX
TO    DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1TV0_A
XR    UniProt: P28311
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GLLCYCRKGH CKRGERVRGT C---GIRFLY CCPRR 
//


ID    AVR/I/SSAP110
ET    Clinical
PN    Cryptdin-4 (Crp-4)
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    a-defensin
SO    Mouse
TX    Animalia (Mouse)
VL    Experimentally validated
XX
TO    DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    Crp-4, along with RMAD-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic, stable in serum and plasma, and significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1TV0_A
XR    UniProt: P28311
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GLLCYCRKGH CKRGERVRGT C---GIRFLY CCPRR 
//


ID    AVR/I/SSAP111
ET    Clinical
PN    RMAD-4
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    myeloid a-defensin
SO    Rhesus macaque
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RRTCRCRFGR CFRRESYGSC NINGRIFSLC CR 
//


ID    AVR/I/SSAP112
ET    Clinical
PN    RMAD-4
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    myeloid a-defensin
SO    Rhesus macaque
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RRTCRCRFGR CFRRESYGSC NINGRIFSLC CR 
//


ID    AVR/I/SSAP113
ET    Clinical
PN    RMAD-4
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    myeloid a-defensin
SO    Rhesus macaque
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RRTCRCRFGR CFRRESYGSC NINGRIFSLC CR 
//


ID    AVR/I/SSAP114
ET    Clinical
PN    RMAD-4
PL    32 [Note: any special compound, if present in sequence, is not considered in length]
SR    myeloid a-defensin
SO    Rhesus macaque
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    RMAD-4, along with Crp-4 and RTD-1, are non-hemolytic peptides. Systemic administration of RMAD-4 to BALB/c mice was non-toxic and stable in serum and plasma, indicating its safety profile in vivo.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RRTCRCRFGR CFRRESYGSC NINGRIFSLC CR 
//


ID    AVR/I/SSAP115
ET    Clinical
PN    RTD-1
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Theta-defensin
SO    rhesus macaque (Macaca mulatta) 
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    Mu50 (VISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1HVZ_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFCRCLCRRG VCRCICTR 
//


ID    AVR/I/SSAP116
ET    Clinical
PN    RTD-1
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Theta-defensin
SO    rhesus macaque (Macaca mulatta) 
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    Mu3 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1HVZ_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFCRCLCRRG VCRCICTR 
//


ID    AVR/I/SSAP117
ET    Clinical
PN    RTD-1
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Theta-defensin
SO    rhesus macaque (Macaca mulatta) 
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    DH 290 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 3 microM
TH    RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1HVZ_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFCRCLCRRG VCRCICTR 
//


ID    AVR/I/SSAP118
ET    Clinical
PN    RTD-1
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Theta-defensin
SO    rhesus macaque (Macaca mulatta) 
TX    Animalia (Rhesus monkey)
VL    Experimentally validated
XX
TO    DH280 (hVISA) (clinical bacterial isolate obtained from hospitalized patients at Huntington Hospital (Pasadena, CA, USA))
IC    MBC = 1.5 microM
TH    RTD-1, along with Crp-4 and RMAD-4, are non-hemolytic peptides. Systemic administration of RTD-1 to BALB/c mice was non-toxic and stable in serum and plasma, and it significantly improved survival in mice with E. coli peritonitis and sepsis induced by cecal ligation-and-puncture.
XR    PubMed: 24345876
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 1HVZ_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFCRCLCRRG VCRCICTR 
//


ID    AVR/I/SSAP119
ET    Clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP120
ET    Clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP121
ET    Clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP122
ET    Clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP123
ET    Clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP124
ET    Clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP125
ET    Clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP126
ET    Clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP127
ET    Clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 8 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB10955
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP128
ET    Clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP129
ET    Clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP130
ET    Clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP131
ET    Clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA01 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP132
ET    Clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA02 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP133
ET    Clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA03 (clinical MDR strain isolate provided by Tsai-Ling Yang, National Health Research Institutes (Miaoli, Taiwan))
IC    MIC = 16 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP134
ET    Non-clinical
PN    Hec
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bee venom
SO    Apis mellifera
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-4
IC    MIC = 80 microM
TH    Moderate toxic effect at high concentrations
XR    PubMed: 30349337
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FALALKALKK ALKKLKKALK KAL 
//


ID    AVR/I/SSAP135
ET    Non-clinical
PN    Cecropin A
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Hyalophora cecropi
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-8
IC    MIC = 64 microG/ML
TH    Low cytotoxic effect on human lung carcinoma
XR    PubMed: 16797106
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2LSA_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2MAG_A
XR    UniProt: C0HKN6
XR    UniProt: P11006
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GIGKFLHSAK KFGKAFVGEI MNS 
//


ID    AVR/I/SSAP136
ET    Non-clinical
PN    Agelaia-MPI
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Parachartergus fraternus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 4-8 microG/ML
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 33244888
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P0DRA8
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      INWLKLGKAI IDAL 
//


ID    AVR/I/SSAP137
ET    Non-clinical
PN    Protonectin
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Agelaia pallipes pallipes
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 16 microG/ML
TH    Toxic to cancerous and non-cancerous cell lines, but moderated hemolytic effect against human erythrocytes
XR    PubMed: 33244888
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 6N68_A
XR    UniProt: P0C1R1
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ILGTILGLLK GL 
//


ID    AVR/I/SSAP138
ET    Non-clinical
PN    NeuroVAL
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Agelaia-MPI analog
SO    Parachartergus fraternus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 128 microG/ML
TH    Non toxic to human erythrocytes, and cancerous and non-cancerous cells lines.
XR    PubMed: 33244888
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ILE-PHE-TR P-LEU-PHE- ARG-GLY-LY S-ALA-ASP- VAL-ALA-LE U-NH2 
      
//


ID    AVR/I/SSAP139
ET    Non-clinical
PN    Protonectin-F
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Protonectin Analog
SO    Agelaia pallipes pallipes
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 16 microG/ML
TH    Toxic to cancerous and non-cancerous cell lines, but moderated hemolytic effect against human erythrocytes
XR    PubMed: 33244888
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IFGTILGFLK GL 
//


ID    AVR/I/SSAP140
ET    Non-clinical
PN    Ctriporin
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Chaerilus tricostatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VRSA-1
IC    MIC = 10 microG/ML
TH    Histological results showed recovery of the skin
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLWGLIPGAV TSLIAISKK 
//


ID    AVR/I/SSAP141
ET    Non-clinical
PN    Ctriporin
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Chaerilus tricostatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VRSA-2
IC    MIC = 10 microG/ML
TH    Histological results showed recovery of the skin
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLWGLIPGAV TSLIAISKK 
//


ID    AVR/I/SSAP142
ET    Non-clinical
PN    Ctriporin
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Chaerilus tricostatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA-1
IC    MIC = 10 microG/ML
TH    Histological results showed recovery of the skin
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLWGLIPGAV TSLIAISKK 
//


ID    AVR/I/SSAP143
ET    Non-clinical
PN    Smp24
PL    24 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA-25
IC    MIC = 32 microG/ML
TH    Toxic to sheep erythrocytes
XR    PubMed: 27019370
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLPSLFGGG -KKDS 
//


ID    AVR/I/SSAP144
ET    Non-clinical
PN    Smp24
PL    24 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Scorpio maurus palmatus
TX    Animalia (Scorpion)
VL    Experimentally validated
XX
TO    VISA-26
IC    MIC = 64 microG/ML
TH    Toxic to sheep erythrocytes
XR    PubMed: 27019370
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IWSFLIKAAT KLLPSLFGGG -KKDS 
//


ID    AVR/I/SSAP145
ET    Non-clinical
PN    Persulcatusin (IP)
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes persulcatus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-3
IC    MIC = 2 microG/ML
TH    Non toxic to fibroblasts, colon, epithelial cells, and erythrocytes
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQGA CHRHCRSIGR RGGYCAGLFK QTCTCYSR 
//


ID    AVR/I/SSAP146
ET    Non-clinical
PN    Persulcatusin (IP)
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes persulcatus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-2
IC    MIC = 8 microG/ML
TH    Non toxic to fibroblasts, colon, epithelial cells, and erythrocytes
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQGA CHRHCRSIGR RGGYCAGLFK QTCTCYSR 
//


ID    AVR/I/SSAP147
ET    Non-clinical
PN    IR
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes ricinus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-3
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGYYCPFFQD KCHRHCRSFG RKAGYCGGFL KKTCICV 
//


ID    AVR/I/SSAP148
ET    Non-clinical
PN    IR
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ixodes ricinus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-2
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GGYYCPFFQD KCHRHCRSFG RKAGYCGGFL KKTCICV 
//


ID    AVR/I/SSAP149
ET    Non-clinical
PN    HAE
PL    35 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Haemaphysalis longicornis
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-3
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GCPLNQGACH NHCRSIGRRG GYCAGIKQTC TCYRK 
//


ID    AVR/I/SSAP150
ET    Non-clinical
PN    HAE
PL    35 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Haemaphysalis longicornis
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-2
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GCPLNQGACH NHCRSIGRRG GYCAGIKQTC TCYRK 
//


ID    AVR/I/SSAP151
ET    Non-clinical
PN    OMBAC
PL    40 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ornithodoros moubata
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-3
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQYE CHAHCSGVPG YPGYKGGYCK GLFKQTCNCY 
//


ID    AVR/I/SSAP152
ET    Non-clinical
PN    OMBAC
PL    40 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Ornithodoros moubata
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VISA-2
IC    MIC => 32 microG/ML
TH    Not available
XR    PubMed: 27531221
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GFGCPFNQYE CHAHCSGVPG YPGYKGGYCK GLFKQTCNCY 
//


ID    AVR/I/SSAP153
ET    Non-clinical
PN    FL10
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fallaxin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-32
IC    MIC = 50 microM
TH    High hemolytic effect on human erythrocytes
XR    PubMed: 17766389
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAL KDIAGHLASK VMNKL 
//


ID    AVR/I/SSAP154
ET    Non-clinical
PN    FL9
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fallaxin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-32
IC    MIC = 50 microM
TH    Moderate hemolytic effect on human erythrocytes
XR    PubMed: 17766389
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGLA KDIAGHLASK VMNKL 
//


ID    AVR/I/SSAP155
ET    Non-clinical
PN    FA12
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fallaxin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-32
IC    MIC = 50 microM
TH    High hemolytic effect on human erythrocytes
XR    PubMed: 17766389
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KAIAGHLASK VMNKL 
//


ID    AVR/I/SSAP156
ET    Non-clinical
PN    FL14
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fallaxin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-32
IC    MIC = 50 microM
TH    High hemolytic effect on human erythrocytes
XR    PubMed: 17766389
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDILGHLASK VMNKL 
//


ID    AVR/I/SSAP157
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VRSA-18
IC    MIC = 64 microG/ML
TH    Low cytotoxic effect
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP158
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VISA-7
IC    MIC = 64 microG/ML
TH    Low cytotoxic effect
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP159
ET    Non-clinical
PN    LL-13
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Derived from LL-37
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-18
IC    MIC = 512 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES 
//


ID    AVR/I/SSAP160
ET    Non-clinical
PN    LL-13
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Derived from LL-37
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-7
IC    MIC = 1024 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES 
//


ID    AVR/I/SSAP161
ET    Non-clinical
PN    LL-17
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Derived from LL-37
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-18
IC    MIC = 512 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP162
ET    Non-clinical
PN    LL-17
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Derived from LL-37
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-7
IC    MIC = 1024 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP163
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-19
IC    MIC = 4.1 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP164
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-20
IC    MIC = 8.3 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP165
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-21
IC    MIC = 4.1 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP166
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-22
IC    MIC = 8.3 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP167
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-23
IC    MIC = 4.1 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP168
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-24
IC    MIC = 8.3 mg/L
TH    Hemolytic effect on sheep erythrocytes
XR    PubMed: 19561147
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP169
ET    Non-clinical
PN    Hominicin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus hominis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-18
IC    MIC = 3.82 microG/ML
TH    Not available
XR    PubMed: 20654578
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Dmlle-Dhb- P-A-Dhb-P- F-Dhb-P-A- I-T-E-I-Dh b-A-A-V-I- A-Dmp 
      
//


ID    AVR/I/SSAP170
ET    Non-clinical
PN    Mutacin 1140
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptococcus mutans
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-23
IC    MIC = 4-8 microG/ML
TH    Not available
XR    PubMed: 20039385
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      F-K-A-W-Dh a-L-A-Abu- P-G-A-A-R- Dhb-G-A-F- N-A-Y-A 
//


ID    AVR/I/SSAP171
ET    Non-clinical
PN    Mutacin 1140
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptococcus mutans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-15
IC    MIC = 4 microG/ML
TH    Not available
XR    PubMed: 20039385
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      F-K-A-W-Dh a-L-A-Abu- P-G-A-A-R- Dhb-G-A-F- N-A-Y-A 
//


ID    AVR/I/SSAP172
ET    Non-clinical
PN    Bactofencin A (analog 5)
PL    22 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactobacillus salivarius
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-25
IC    MIC = 4.3 microM
TH    Not available
XR    PubMed: 30540905
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      KRKKHRCRVW NNGLPTGLYR WC 
//


ID    AVR/I/SSAP173
ET    Non-clinical
PN    Bactofencin A (analog 5)
PL    22 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactobacillus salivarius
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-26
IC    MIC = 100 microM
TH    Not available
XR    PubMed: 30540905
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      KRKKHRCRVW NNGLPTGLYR WC 
//


ID    AVR/I/SSAP174
ET    Non-clinical
PN    Lugdunin
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus lugdunensis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-30
IC    MIC = 3 microG/ML
TH    No lysis of primary human erythrocytes or neutrophils.
XR    PubMed: 27466123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thiazolidi ne-Val-Trp -Leu-Val-V al 
//


ID    AVR/I/SSAP175
ET    Non-clinical
PN    P138-C
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus subtilis subsp. inaquosorum
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-14
IC    MIC = 20 microG/ML
TH    Not available
XR    PubMed: 28581021
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Gly-Leu-Gl u-Glu-Thr- Val-Tyr-Il e-Tyr-Gly- Ala-Asn-Me t-X-Ser 
      
//


ID    AVR/I/SSAP176
ET    Non-clinical
PN    CSPK14
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus amyloliquefaciens
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-13
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 27787755
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      HYDPGDDSGN TG 
//


ID    AVR/I/SSAP177
ET    Non-clinical
PN    LI-F04a analog 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fusaricidin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-29
IC    MIC = 16 microG/ML
TH    Hemolysis on human erythrocytes
XR    PubMed: 22392790
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr-Val-Va l-Thr-Asn- Ala 
//


ID    AVR/I/SSAP178
ET    Non-clinical
PN    LI-F04a analog 6
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fusaricidin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-29
IC    MIC = 16 microG/ML
TH    Hemolysis on human erythrocytes
XR    PubMed: 22392790
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr-Val-Va l-Thr-Asn- Ala 
//


ID    AVR/I/SSAP179
ET    Non-clinical
PN    LI-F04a analog 8
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fusaricidin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-29
IC    MIC = 16 microG/ML
TH    Hemolysis on human erythrocytes
XR    PubMed: 22392790
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr-Val-Al a-Thr-Asn- Ala 
//


ID    AVR/I/SSAP180
ET    Non-clinical
PN    LI-F04a analog 11
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Fusaricidin analogs
TX    Not available
VL    Experimentally validated
XX
TO    VISA-29
IC    MIC = 16 microG/ML
TH    Hemolysis on human erythrocytes
XR    PubMed: 22392790
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr-Val-Ph e-Thr-Asn- Ala 
//


ID    AVR/I/SSAP181
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-5
IC    MIC = 2-4 microG/ML
TH    Phase III of a clinical trial
XR    PubMed: 22585222
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP182
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-3
IC    MIC = 2-4 microG/ML
TH    Phase III of a clinical trial
XR    PubMed: 22585222
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP183
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-19
IC    MIC = 16 microG/ML
TH    Topical antimicrobial agent in phase III of a clinical trial
XR    PubMed: 18178361
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP184
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-10
IC    MIC = 16 microG/ML
TH    Topical antimicrobial agent in phase III of a clinical trial
XR    PubMed: 18178361
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP185
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-11
IC    MIC = 16 microG/ML
TH    Topical antimicrobial agent in phase III of a clinical trial
XR    PubMed: 18178361
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP186
ET    Non-clinical
PN    MP196
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-16
IC    MIC = 16 microM
TH    Light hemolytic effect on cell lines of breast cancer. Acute toxicity in mice cells
XR    PubMed: 27617260
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWRWRW-NH2 
//


ID    AVR/I/SSAP187
ET    Non-clinical
PN    MP196
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-17
IC    MIC = 64 microG/ML
TH    Light hemolytic effect on cell lines of breast cancer. Acute toxicity in mice cells
XR    PubMed: 27617260
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWRWRW-NH2 
//


ID    AVR/I/SSAP188
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-20
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP189
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-21
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP190
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-22
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP191
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-12
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP192
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-13
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP193
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-14
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac-A-K-R-H -H-G-Y-K-R -K-F-H-NH2 
//


ID    AVR/I/SSAP194
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-20
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP195
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-21
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP196
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-22
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP197
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-12
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP198
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-13
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP199
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-14
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-F -F-G-Y-K-R -K-F-F-NH2 
//


ID    AVR/I/SSAP200
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-20
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP201
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-21
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP202
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-22
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP203
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-12
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP204
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-13
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP205
ET    Non-clinical
PN    Bip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-14
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-B ip-Bip-G-Y -K-R-K-F-B ip-NH2 
//


ID    AVR/I/SSAP206
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-20
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP207
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-21
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP208
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-22
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP209
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-12
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP210
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-13
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP211
ET    Non-clinical
PN    Dip-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-14
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-A-K-R-D ip-Dip-G-Y -K-R-K-F-D ip-NH2 
//


ID    AVR/I/SSAP212
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-20
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP213
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-21
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP214
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-22
IC    MIC = 16 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP215
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-12
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP216
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-13
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP217
ET    Non-clinical
PN    Nal-P-113
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-14
IC    MIC = 8 microG/ML
TH    Not available
XR    PubMed: 32605123
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac-AKR-Nal -Nal-GYKRK F-Nal-NH2 
//


ID    AVR/I/SSAP218
ET    Non-clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 0.5 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP219
ET    Non-clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 0.6 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP220
ET    Non-clinical
PN    Lipopeptide 1
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 0.7 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Leu-D -Tyr-D-Phe -D-Ser-D-T hr-) 
//


ID    AVR/I/SSAP221
ET    Non-clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 2.8 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP222
ET    Non-clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 1.9 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP223
ET    Non-clinical
PN    Lipopeptide 2
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 2.8 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(LLYF STD) 
//


ID    AVR/I/SSAP224
ET    Non-clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP225
ET    Non-clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP226
ET    Non-clinical
PN    Lipopeptide 3
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Leu-D -Phe-D-Leu -) 
//


ID    AVR/I/SSAP227
ET    Non-clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP228
ET    Non-clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP229
ET    Non-clinical
PN    Lipopeptide 4
PL    4 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 30 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -) 
//


ID    AVR/I/SSAP230
ET    Non-clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 0.2 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP231
ET    Non-clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 0.1 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP232
ET    Non-clinical
PN    Lipopeptide 5
PL    6 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 0.1 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-L eu-D-Tyr-D -Leu-D-Phe -D-Pro-D-V al-) 
//


ID    AVR/I/SSAP233
ET    Non-clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-15
IC    MIC = 2.8 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP234
ET    Non-clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-16
IC    MIC = 1.9 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP235
ET    Non-clinical
PN    Lipopeptide 6
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-17
IC    MIC = 1.9 microM
TH    Low toxicity in human embryonic and kidney cells
XR    PubMed: 27048775
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Cyclo(-D-P he-D-Val-L -Thr-D-Leu -D-Leu-) 
//


ID    AVR/I/SSAP236
ET    Non-clinical
PN    C14-KK
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 12.5 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-KK 
//


ID    AVR/I/SSAP237
ET    Non-clinical
PN    C14-RRR
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 3.1 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-RRR 
//


ID    AVR/I/SSAP238
ET    Non-clinical
PN    C14-LK
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 1.56 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-LK 
//


ID    AVR/I/SSAP239
ET    Non-clinical
PN    C14-LK
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 12.5 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-RW 
//


ID    AVR/I/SSAP240
ET    Non-clinical
PN    C14-WR
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 3.1 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-WR 
//


ID    AVR/I/SSAP241
ET    Non-clinical
PN    C14-KWI
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 12.5 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-KWI 
//


ID    AVR/I/SSAP242
ET    Non-clinical
PN    C14-LKK
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-31
IC    MIC = 3.1 microM
TH    Strong hemolytic effect on human erythrocytes
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      C14-LKK 
//


ID    AVR/I/SSAP243
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-33
IC    MIC = 2 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP244
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-29
IC    MIC = 4 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP245
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-30
IC    MIC = 4 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP246
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-31
IC    MIC = 4 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP247
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-32
IC    MIC = 4 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP248
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 4 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP249
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA-33
IC    MIC = 16 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP250
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-29
IC    MIC = 32 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP251
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-30
IC    MIC = 16 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP252
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-31
IC    MIC = 16 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP253
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-32
IC    MIC = 32 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP254
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA-33
IC    MIC = 32 microM
TH    Low hemolytic activity, but show toxicity in mammalian cell lines
XR    PubMed: 24798285
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP255
ET    Non-clinical
PN    Mersacidin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus sp. strain HIL Y-85, 54728
TX    Bacteria
VL    Experimentally validated
XX
TO    VSSA strain SG511
IC    MIC = 1 microG/ML
TH    Not available
XR    PubMed: 18947397
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      A-Abu-I-Ab u-L-P-C-G- G-G-V-A-Ab u-L-Abu-Dh a-E-A-I 
//


ID    AVR/I/SSAP256
ET    Non-clinical
PN    BCP61
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus sp.
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA-24
IC    MIC = 10 microG/ML
TH    Not available
XR    PubMed: 22578764
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      AINCDAAYL 
//


ID    AVR/I/SSAP257
ET    Non-clinical
PN    AgkTx-II (PLA2)
PL    47 [Note: any special compound, if present in sequence, is not considered in length]
SR    Agelena orientalis venom
SO    Agelena orientalis
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 21.25 (83.6%) microG/ML, MBC (Colony forming units/ML) = (6) 80%
TH    Not available
XR    PubMed: 22050758
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GIDCGKAGKP CPCKKPCKKS CRFSFAYPFC GRGKQYRKMK ADCCSCK 
//


ID    AVR/I/SSAP258
ET    Non-clinical
PN    Crotoxin B 
PL    134 [Note: any special compound, if present in sequence, is not considered in length]
SR    Crotalus durissus terrificus venom
SO    Crotalus durissus terrificus
TX    Animalia (Snake)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = nt, MBC = nt
TH    Not available
XR    PubMed: 22050758
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      MSPDFYAYFK ILKVKEEYGP CGVSNPWCYC TSSDNEIVCK KNGNACIEGC EPYCRGRGAA 
      GTCRDSGKPK DATCDAVLKC YKSGKRCLPT KYGFGGFYNR PDDYFKDPKT MGAVCGEMFR 
      KDLVKWCKKG CKKP 
//


ID    AVR/I/SSAP259
ET    Non-clinical
PN    Daboiatoxin (DbTx)
PL    64 [Note: any special compound, if present in sequence, is not considered in length]
SR    Daboia russelii venom
SO    Daboia russelii
TX    Animalia (Snake)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = nt, MBC = nt
TH    Not available
XR    PubMed: 22050758
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      MDFPYAFKCM  KDVVYTAAQ Y KKWVRYRA GC CGGNTAD SYC NAICTN RRIC FSDEC 
      QRFNP DCQS 
//


ID    AVR/I/SSAP260
ET    Non-clinical
PN    Mulgatoxin
PL    76 [Note: any special compound, if present in sequence, is not considered in length]
SR    Pseudechis australis venom
SO    Pseudechis australis
TX    Animalia (Snake)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = nt, MBC = nt
TH    Not available
XR    PubMed: 22050758
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      MKLFWLLVVG  AFLGLVQGP H RIGGQNIE KT IENLKNE TAE ALKWNA KQEK VDEII 
      AIKEK AEEL KEAFGK YAK SSS 
//


ID    AVR/I/SSAP261
ET    Non-clinical
PN    Metalloproteinases (AHM)
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Agkistrodon halys (pallas, Chinese viper) snake venom
SO    Agkistrodon halys (pallas, Chinese viper) snake 
TX    Animalia (Snake)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 7.5 (80.9%) microG/ML, MBC = (7) 83.7% 
TH    Not available
XR    PubMed: 22050758
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P83253
XR    UniProt: C9E1S2
XR    UniProt: Q805F5
XR    UniProt: Q2LD49
XR    UniProt: P20164
XR    UniProt: Q90ZI3
XR    UniProt: Q8AWI5
XR    UniProt: Q8AWX7
XR    UniProt: J9Z332
XR    UniProt: J3SBP9
XR    UniProt: C9E1R7
XR    UniProt: P83912
XR    UniProt: E9NW27
XR    UniProt: P0C6B6
XR    UniProt: P18619
XR    UniProt: P17349
XR    UniProt: Q90YA6
XR    UniProt: Q7ZZS9
XR    UniProt: E9NW26
XR    UniProt: C9E1R9
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      MIQVLLVTIC LAVFPYQGSS IILES 
//


ID    AVR/I/SSAP262
ET    Non-clinical
PN    Bactofencin A
PL    42 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Gram-positive bacteria, such as those from lactic acid bacteria
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 40410425
IC    MIC = 100 microM
TH    Not available
XR    PubMed: 30540905
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GKGLVAKGAL SKVKAGVGAG KAGVVKALPA AKAVKVLAAK AA 
//


ID    AVR/I/SSAP263
ET    Non-clinical
PN    Bactofencin A
PL    42 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Gram-positive bacteria, such as those from lactic acid bacteria
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 40413389
IC    MIC = 4.3 microM
TH    Not available
XR    PubMed: 30540905
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GKGLVAKGAL SKVKAGVGAG KAGVVKALPA AKAVKVLAAK AA 
//


ID    AVR/I/SSAP264
ET    Non-clinical
PN    BCP61
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus subtilis BSn5
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 10 microG/ML
TH    Not available
XR    PubMed: 22578764
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      A-I-N-X-D- A-A-Y-L 
//


ID    AVR/I/SSAP265
ET    Non-clinical
PN    Fallaxin
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5U9S_A
XR    UniProt: C0HKF0
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP266
ET    Non-clinical
PN    FA25
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK VMNKA-NH2 
//


ID    AVR/I/SSAP267
ET    Non-clinical
PN    FA24
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    2% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK VMNAL-NH2 
//


ID    AVR/I/SSAP268
ET    Non-clinical
PN    FA23
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK VMAKL-NH2 
//


ID    AVR/I/SSAP269
ET    Non-clinical
PN    FA22
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK VANKL-NH2 
//


ID    AVR/I/SSAP270
ET    Non-clinical
PN    FA21
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASK AMNKL-NH2 
//


ID    AVR/I/SSAP271
ET    Non-clinical
PN    FA20
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    2% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLASA VMNKL-NH2 
//


ID    AVR/I/SSAP272
ET    Non-clinical
PN    FA19
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    2% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLAAK VMNKL-NH2 
//


ID    AVR/I/SSAP273
ET    Non-clinical
PN    FA18
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    38% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHLLSK VMNKL-NH2 
//


ID    AVR/I/SSAP274
ET    Non-clinical
PN    FA17
PL    24 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGHASKV MNKL-NH2 
//


ID    AVR/I/SSAP275
ET    Non-clinical
PN    FA16
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGALASK VMNKL-NH2 
//


ID    AVR/I/SSAP276
ET    Non-clinical
PN    FA15
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    14% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAAHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP277
ET    Non-clinical
PN    FA14
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 50 microM
TH    55% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDILGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP278
ET    Non-clinical
PN    FA13
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDAAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP279
ET    Non-clinical
PN    FA12
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 50 microM
TH    32% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KAIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP280
ET    Non-clinical
PN    FA11
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    5% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA ADIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP281
ET    Non-clinical
PN    FA10
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 50 microM
TH    43% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAL KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP282
ET    Non-clinical
PN    FA9
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 50 microM
TH    27% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGLA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP283
ET    Non-clinical
PN    FA8
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    11% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKAAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP284
ET    Non-clinical
PN    FA7
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILAGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP285
ET    Non-clinical
PN    FA6
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDIAKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP286
ET    Non-clinical
PN    FA5
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDALKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP287
ET    Non-clinical
PN    FA4
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    1% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVAILKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP288
ET    Non-clinical
PN    FA3
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVADILKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP289
ET    Non-clinical
PN    FA2
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GAVDILKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP290
ET    Non-clinical
PN    FA1
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 100 microM
TH    0% hemolytic activity found at the tested concentration for VISA.
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      AVVDILKGAA KDIAGHLASK VMNKL-NH2 
//


ID    AVR/I/SSAP291
ET    Non-clinical
PN    FNt17-25
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA ATCC 700699 MU50
IC    MIC = 100 microM
TH    Not available
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      LASKVMNKL- NH2 
//


ID    AVR/I/SSAP292
ET    Non-clinical
PN    FCt1-11
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA ATCC 700699MU50
IC    MIC = 100 microM
TH    Not available
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA K-NH2 
//


ID    AVR/I/SSAP293
ET    Non-clinical
PN    FCt1-16
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    West Indian mountain chicken frog Leptodactylus fallax
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA ATCC 700699MU50
IC    MIC = 100 microM
TH    Not available
XR    PubMed: 17766389
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5U9S_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5U9R_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5U9Q_A
XR    UniProt: C0HKF0
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      GVVDILKGAA KDIAGH-NH2 
//


ID    AVR/I/SSAP294
ET    Non-clinical
PN    Daptomycin
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptomyces roseosporus
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC(90%) = NA, MIC RANGE = 0.25 to 1 microG/ML
TH    Daptomycin has demonstrated a favorable safety profile in both animal toxicology studies and clinical trials, including a Phase I trial assessing its tolerability and pharmacokinetics in hemodialysis patients with end-stage renal disease. Daptomycin also can cause dose-dependent hemolysis, especially in patients with renal impairment or on high doses, necessitating monitoring for anemia or hemoglobin changes during therapy.
XR    PubMed: 15330747
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00080
XX
SQ    SEQUENCE  
      Thr-D-Asn- Glu-Tyr-As n-Pro-L-As n-Gly-L-Th r-L-Ser-D- Asn-Gly-L- 
      Thr-L-Thr- L-Cys-L-Th r 
//


ID    AVR/I/SSAP295
ET    Non-clinical
PN    Daptomycin
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptomyces roseosporus
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC(90%) = 1 microG/ML, MIC RANGE = 0.0625 to 2 microG/ML
TH    Daptomycin has demonstrated a favorable safety profile in both animal toxicology studies and clinical trials, including a Phase I trial assessing its tolerability and pharmacokinetics in hemodialysis patients with end-stage renal disease. Daptomycin also can cause dose-dependent hemolysis, especially in patients with renal impairment or on high doses, necessitating monitoring for anemia or hemoglobin changes during therapy.
XR    PubMed: 15330747
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00080
XX
SQ    SEQUENCE  
      Thr-D-Asn- Glu-Tyr-As n-Pro-L-As n-Gly-L-Th r-L-Ser-D- Asn-Gly-L- 
      Thr-L-Thr- L-Cys-L-Th r 
//


ID    AVR/I/SSAP296
ET    Non-clinical
PN    Phormicin C
PL    40 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Musca domestica
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA-27
IC    MIC = 32 microG/ML
TH    Not available
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ATCDLLSGTG VGHSACAAHC LLRGNRGGYC NGKGVCVCRN 
//


ID    AVR/I/SSAP297
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32679
IC    MIC = 4.1 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP298
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 35197
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP299
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32652
IC    MIC = 4.1 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP300
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32675
IC    MIC = 4.1 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP301
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32681
IC    MIC = 2 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP302
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22783
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP303
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 24764
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP304
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22796
IC    MIC = 4.1 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP305
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 25949
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP306
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 29369
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP307
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22797
IC    MIC = 8.3 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP308
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32679
IC    MIC = 15.4 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP309
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 35197
IC    MIC = 30.9 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP310
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32652
IC    MIC = 15.4 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP311
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32675
IC    MIC = 30.9 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP312
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    hVISA 32681
IC    MIC = 30.9 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP313
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22783
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP314
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 24764
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP315
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22796
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP316
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 25949
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP317
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 29369
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP318
ET    Non-clinical
PN    Lacticin 3147
PL    50 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 22797
IC    MIC = 61.8 mg/L
TH    Not available
XR    PubMed: 19561147
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      NH2-Ala-Al a-Dhb-Asn- Dhb-Phe-D  Ala-Leu-Al a-Asp-Tyr- Trp-Gly-As 
      n-Asn-Gly- Ala-Trp-Al a-Abu-Leu- Abu-His-Gl u-Ala-Met- Ala-Trp-Al 
      a-Lys-COOH  + Dhb-Pro -Ala-Dhb-P ro-Ala-Ile -D Ala-Ile -Leu-D Ala 
      -Ala-Tyr-I le-Ala-Thr -Asn-Thr-A la-Pro-Abu -Thr-Lys-A la-Abu-Arg 
      -Ala-Ala 
//


ID    AVR/I/SSAP319
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS1
IC    MIC = 2 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP320
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS19
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP321
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS37
IC    MIC = 2 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP322
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 1
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP323
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 2
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP324
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 3a
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP325
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 4
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP326
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 5
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP327
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 6
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP328
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 7
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP329
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 8
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP330
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 9
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP331
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 10
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP332
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 11b
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP333
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 12
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP334
ET    Non-clinical
PN    RRIKA
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 13
IC    MIC = 4 microM
TH    RRIKA caused minimal hemolysis in human erythrocytes even at 300microM, exhibited no toxicity to HeLa cells up to 32microM (8 times its MIC), and had an EC50 of 64microM against macrophages, showing significantly lower toxicity compared to melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR RIKA 
//


ID    AVR/I/SSAP335
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS1
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP336
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS19
IC    MIC = 8 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP337
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS37
IC    MIC = 8 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP338
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 1
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP339
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 2
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP340
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 3a
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP341
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 4
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP342
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 5
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP343
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 6
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP344
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 7
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP345
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 8
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP346
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 9
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP347
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 10
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP348
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 11b
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP349
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 12
IC    MIC = 32 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP350
ET    Non-clinical
PN    RR
PL    11 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA 13
IC    MIC = 16 microM
TH    RR demonstrated minimal toxicity to HeLa cells up to 64microM and low hemolytic activity with a maximum of 10% hemolysis at 300microM, making it a promising antimicrobial agent compared to the highly toxic melittin.
XR    PubMed: 24798285
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7YSS_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      WLRRIKAWLR R 
//


ID    AVR/I/SSAP351
ET    Non-clinical
PN    Mersacidin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus sp
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-27
IC    MIC = 35 microG/ML
TH    Not available
XR    PubMed: 18947397
XR    PubMed: 34360692
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      A-Abu-I-Ab u-L-P-C-G- G-G-V-A-Ab u-L-Abu-Dh a-E-A-I 
//


ID    AVR/I/SSAP352
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    hVISA
IC    MIC(50%) = 16 microG/ML, MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 18178361
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP353
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA
IC    MIC(50%) = 16 microG/ML, MIC(90%) = 32 microG/ML
TH    Not available
XR    PubMed: 18178361
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP354
ET    Non-clinical
PN    Omiganan (Indolicidin analog)
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA
IC    MIC(50%) = 16 microG/ML, MIC(90%) = NIL
TH    Not available
XR    PubMed: 18178361
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06610
XX
SQ    SEQUENCE  
      ILRWPWWPWR RK-amide 
//


ID    AVR/I/SSAP355
ET    Non-clinical
PN    Mutacin 1140
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptococcus mutans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    Cmax = 11.0 +- 4.1 microG/ML
TH    Not available
XR    PubMed: 20039385
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      F-K-A-W-Dh a-L-A-Abu- P-G-A-A-R- Dhb-G-A-F- N-A-Y-A 
//


ID    AVR/I/SSAP356
ET    Non-clinical
PN    Mutacin 1140
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Streptococcus mutans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    Cmax = 21.0 +- 12.6 microG/ML
TH    Not available
XR    PubMed: 20039385
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      F-K-A-W-Dh a-L-A-Abu- P-G-A-A-R- Dhb-G-A-F- N-A-Y-A 
//


ID    AVR/I/SSAP357
ET    Non-clinical
PN    CSPK14
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Skin secretion of the frog species Bacillus amyloliquefaciens subsp. plantarum FZB42(T)
SO    Bacillus amyloliquefaciens subsp. plantarum FZB42(T)
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 64 microG/ML
TH    Not available
XR    PubMed: 27787755
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      HYDPGDDSGN TG 
//


ID    AVR/I/SSAP358
ET    Non-clinical
PN    Fusaricidin A/LI-F04a
PL    19 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Staphylococcus aureus Mu50 (VRSA) ATCC 700699
IC    MIC =>128 microG/ML
TH    Depsipeptides 6, 8, and 11 showed hemolytic activity at higher concentrations, correlating with their hydrophobicity, while amide analogues 1416 had no appreciable hemolytic activity. DMSO presence in the assay may enhance hemolysis due to potential peptide aggregation at higher concentrations. Depsipeptides 4 and 6 were cytotoxic to WRL 68 and HepG2 cell lines at higher concentrations, unlike amide analogue 14, which exhibited much lower cytotoxicity. The lack of cytotoxicity in amide analogue 14 is likely due to its conformational differences and lower hydrophobicity compared to the depsipeptides.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      D-Asn-D-As n-D-Ser-L- Tyr-L-Asn- L-Asn-D-As n-L-Asn-D- Ser-L-Thr- 
      L-Gln-D-As n-D-Asn-D- Ser-L-Tyr- L-Asn-L-As n-D-Asn-D- Asn 
      
//


ID    AVR/I/SSAP359
ET    Non-clinical
PN    Agelaia-MPI
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Venom of Parachartergus fraternus
SO    Parachartergus fraternus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    S. aureus VRSA
IC    MIC = 4-8 microG/ML
TH    Agelaia-MPI was found to be hemolytic and toxic to cancerous and non-cancerous cell lines. Agelaia-MPI showed hemolytic activity with a hemolytic concentration to lyse 50% of red blood cells (HC50) of 11.5 plusminus 1.1 microM. Agelaia-MPI also exhibited cytotoxic activity against cancerous cells with a CC50 >32 microM and non-cancerous cells with a CC50 >32 microM.
XR    PubMed: 33244888
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P0DRA8
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      INWLKLGKAI IDAL 
//


ID    AVR/I/SSAP360
ET    Non-clinical
PN    NeuroVAL
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Venom of Parachartergus fraternus
SO    Parachartergus fraternus
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    S. aureus VRSA
IC    MIC = 128 microG/ML
TH    Not available
XR    PubMed: 33244888
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7JGX_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ILE-PHE-TR P-LEU-PHE- ARG-GLY-LY S-ALA-ASP- VAL-ALA-LE U-NH2 
      
//


ID    AVR/I/SSAP361
ET    Non-clinical
PN    Protonectin
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Venom of Agelaia pallipes pallipes
SO    Agelaia pallipes pallipes
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    S. aureus VRSA
IC    MIC = 16 microG/ML
TH    Protonectin showed cytotoxic activity against both cancerous and non-cancerous cells.
XR    PubMed: 33244888
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 6N68_A
XR    UniProt: P0C1R1
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ILGTILGLLK GL 
//


ID    AVR/I/SSAP362
ET    Non-clinical
PN    Protonectin-F
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Venom of Agelaia pallipes pallipes
SO    Agelaia pallipes pallipes
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    S. aureus VRSA
IC    MIC = 16 microG/ML
TH    Protonectin-F was found to be toxic to cancerous and non-cancerous cell lines. Specifically, Protonectin-F showed activity against MM96L cells, with a cytotoxic concentration (CC50) close to the concentration necessary to kill the correlated non-cancer cell HaCaT. The cytotoxic concentrations (CC50) of Protonectin-F were also more active toward HCT116, with a CC50 <10microM, and twice the concentration of Protonectin-F was necessary to kill the correlated non-cancer cell HEK293 (CC50 19microM).
XR    PubMed: 33244888
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 7JHF_A
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IFGTILGFLK GL 
//


ID    AVR/I/SSAP363
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 1
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 128 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-T hr4-D-Asn5 -D-Ala6 
//


ID    AVR/I/SSAP364
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 2
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 128 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP365
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 3
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 128 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-T hr4-D-Asn5 -D-Ala6 
//


ID    AVR/I/SSAP366
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 4
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 128 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP367
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 5
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 16 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-T hr4-D-Asn5 -D-Ala6 
//


ID    AVR/I/SSAP368
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 6
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 16 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP369
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 7
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 64 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-A la4-D-Asn5 -D-Ala6 
//


ID    AVR/I/SSAP370
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 8
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 16 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Ala3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP371
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 9
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 64 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Ala 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP372
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 10
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 64 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-a Thr4-D-Asn 5-Gly6 
//


ID    AVR/I/SSAP373
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 11
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 16 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Tyr3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP374
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 12
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = Not available
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Phe3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP375
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 13
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 64 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      ELys1-D-Va l2-Val3-D- aThr4-D-As n5 
//


ID    AVR/I/SSAP376
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 14
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = 16 microG/ML
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Dap1-D-Val 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP377
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 15
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = Not available
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Dap1-D-Val 2-Ala3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP378
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 16
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = Not available
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Dap1-D-Val 2-Phe3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP379
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 17
PL    5 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = Not available
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Dap1-D-Val 2-Tyr3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP380
ET    Non-clinical
PN    Fusaricidin A/LI-F04a analogues compound 18
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Paenibacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    Mu50 (VRSA) ATCC 700699
IC    MIC = Not available
TH    The cytotoxicity of analogues 1-18 was assessed using the MTT assay on WRL 68 and HepG2 cell lines. Lipidated depsipeptide analogues 4 and 6 were cytotoxic at higher concentrations, with analogue 6 being highly cytotoxic at 90 mg/mL. In contrast, amide analogue 14 exhibited much lower cytotoxicity at the same concentrations. Moreover, None of the amide analogues 14-17 nor the linear peptide 18 showed hemolytic activity at concentrations eight times the MIC, indicating that ring opening due to ester bond hydrolysis is not responsible for hemolysis.
XR    PubMed: 22392790
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Thr1-D-Val 2-Val3-D-a Thr4-D-Asn 5-D-Ala6 
//


ID    AVR/I/SSAP381
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin found in epithelial cells and neutrophils
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VSSA303
IC    MIC = 5 microG/ML
TH    Not available
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP382
ET    Non-clinical
PN    Polymyxin B
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus polymyxa[T2]
TX    Bacteria
VL    Experimentally validated
XX
TO    VSSA303
IC    MIC = 50 microG/ML
TH    Not available
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00781
XX
SQ    SEQUENCE  
      D-Leu-D-Le u-D-Thr-D- Pro-D-Leu- D-Val-D-Va l-D-Asp-D- Glu-D-Ile- 
      D-Asn-D-Le u-D-Ala-D- Ala-D-Ala- D-Trp-D-Ph e-D-Thr 
//


ID    AVR/I/SSAP383
ET    Non-clinical
PN    LL-13
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP18)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    ATCC 700699(S.aureus strain)
IC    MIC = 1024 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES 
//


ID    AVR/I/SSAP384
ET    Non-clinical
PN    LL-17
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    ATCC 700699(S.aureus strain)
IC    MIC = 1024 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 6S6M_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FBS_N
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 8DEW_D
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5XNG_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2L5M_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX2
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FKRIVQRIKD FLR 
//


ID    AVR/I/SSAP385
ET    Non-clinical
PN    LL-13
PL    25 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    BR-VRSA
IC    MIC = 512 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES 
//


ID    AVR/I/SSAP386
ET    Non-clinical
PN    LL-17
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    BR-VRSA
IC    MIC = 512 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 6S6M_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FBS_N
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 8DEW_D
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 5XNG_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2L5M_A
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2FCG_F
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX2
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FKRIVQRIKD FLR 
//


ID    AVR/I/SSAP387
ET    Non-clinical
PN    LL-13+LL-17+vancomycin
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    ATCC 700699(S.aureus strain)
IC    FIC = 0.06 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES + FK RIVQRIKDFL R 
//


ID    AVR/I/SSAP388
ET    Non-clinical
PN    LL-13+LL-17+vancomycin
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    ATCC 700699(S.aureus strain)
IC    FIC = 1 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES + FK RIVQRIKDFL R 
//


ID    AVR/I/SSAP389
ET    Non-clinical
PN    LL-13+LL-17+vancomycin
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    BR-VRSA
IC    FIC = 0.13 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES + FK RIVQRIKDFL R 
//


ID    AVR/I/SSAP390
ET    Non-clinical
PN    LL-13+LL-17+vancomycin
PL    38 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin (hCAP19)
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    BR-VRSA
IC    FIC = 0.13 microG/ML
TH    Not available
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      IGKEFKRIVQ RIKDFLRNLV PRTES + FK RIVQRIKDFL R 
//


ID    AVR/I/SSAP391
ET    Non-clinical
PN    Hecate(Hec)
PL    23 [Note: any special compound, if present in sequence, is not considered in length]
SR    Bee venom
SO    Apis mellifera
TX    Animalia (Insect)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 80 microM
TH    Not available
XR    PubMed: 30349337
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FALAL-KALK KALKKLKKAL KKAL 
//


ID    AVR/I/SSAP392
ET    Non-clinical
PN    Cerein 7B(Bacteriocin)
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus cereus Bc7
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 20 microG/ML
TH    Not available
XR    PubMed: 37370267
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      N-Gly-Trp- Trp-Asn-Se r-Trp-Gly- Lys 
//


ID    AVR/I/SSAP393
ET    Non-clinical
PN    Cerein 7B(Bacteriocin)
PL    8 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus cereus Bc7
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 
IC    MIC = 20 microG/ML
TH    Not available
XR    PubMed: 37370267
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      N-Gly-Trp- Trp-Asn-Se r-Trp-Gly- Lys 
//


ID    AVR/I/SSAP394
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin found in epithelial cells and neutrophils
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    VISA072
IC    MIC = 5 microG/ML
TH    Not available
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP395
ET    Non-clinical
PN    Polymyxin B
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus polymyxa[T2]
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA072
IC    MIC = 50 microG/ML
TH    Not available
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00781
XX
SQ    SEQUENCE  
      D-Leu-D-Le u-D-Thr-D- Pro-D-Leu- D-Val-D-Va l-D-Asp-D- Glu-D-Ile- 
      D-Asn-D-Le u-D-Ala-D- Ala-D-Ala- D-Trp-D-Ph e-D-Thr 
//


ID    AVR/I/SSAP396
ET    Non-clinical
PN    Pexiganan
PL    21 [Note: any special compound, if present in sequence, is not considered in length]
SR    Skin
SO    African clawed frog
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VRSA
IC    EC50 = 32 microM
TH    Exhibit low toxicity to mammalian cells.
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB16293
XX
SQ    SEQUENCE  
      Gly-Ile-Gl y-Lys-Phe- Leu-Lys-Ly s-Ala-Lys- Lys-Phe-Gl y-Lys-Ala- 
      Phe-Val-Ly s-Ile-Leu- Lys-Lys-NH 2 
//


ID    AVR/I/SSAP397
ET    Non-clinical
PN    WR12 + D-1K8
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic conjugation
TX    Not available
VL    Experimentally validated
XX
TO    VRSA
IC    FIC index of 0.27
TH    Not available
XR    PubMed: 27405275
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      RWWRWWRRWW RR + IRIKI RIK 
//


ID    AVR/I/SSAP398
ET    Non-clinical
PN    MSI-843
PL    22 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Xenopus laevis 
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 1.6 to 12.5 microM
TH    MSI-843, has broad-spectrum antimicrobial activity without observable hemolytic activity.
XR    PubMed: 20459377
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      G-I-G-K-F- L-K-K-A-K- K-F-G-K-A- F-V-K-I-L- K-K-NH2 
//


ID    AVR/I/SSAP399
ET    Non-clinical
PN    YD1
PL    10 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus amyloliquefaciens CBSYD1
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 128 microG/ML
TH    YD1 was not toxic to RAW 264.7 macrophage cells even at a concentration of 120microg/mL. The study demonstrated that YD1 did not exhibit cytotoxicity and showed high cell viability in macrophage cells.
XR    PubMed: 28050849
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ala-Pro-Ly s-Gly-Val- Gln-Gly-Pr o-Asn-Gly  
//


ID    AVR/I/SSAP400
ET    Non-clinical
PN    NZ2114
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Defensin
SO    Pseudoplectania nigrella
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 2 (Pennsylvania HIP11983)
IC    Emax = 4 mg/L (At pH 7.4)
TH    Not available
XR    PubMed: 20534628
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Glu-Val-Pr o-Trp-Asn- Pro-Ala-Pr o-Pro-Pro- Pro-Pro-Pr o-Pro-Pro- 
      Pro-Pro 
//


ID    AVR/I/SSAP401
ET    Non-clinical
PN    NZ2114
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Defensin
SO    Pseudoplectania nigrella
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 2 (Pennsylvania HIP11983)
IC    Emax = 64 mg/L (At lower acidic pH)
TH    Not available
XR    PubMed: 20534628
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Glu-Val-Pr o-Trp-Asn- Pro-Ala-Pr o-Pro-Pro- Pro-Pro-Pr o-Pro-Pro- 
      Pro-Pro 
//


ID    AVR/I/SSAP402
ET    Non-clinical
PN    Daptomycin
PL    30 [Note: any special compound, if present in sequence, is not considered in length]
SR    Soil
SO    Streptomyces roseosporus
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 2 (Pennsylvania HIP11983)
IC    Emax = 1 mg/L (At pH 7.4)
TH    Have a low potential for causing hemolysis.
XR    PubMed: 20534628
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00080
XX
SQ    SEQUENCE  
      KEDNKVYGN- GTPSTCGTQQ PKVGSNNYGK T 
//


ID    AVR/I/SSAP403
ET    Non-clinical
PN    Daptomycin
PL    30 [Note: any special compound, if present in sequence, is not considered in length]
SR    Soil
SO    Streptomyces roseosporus
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA 2 (Pennsylvania HIP11983)
IC    Emax = 16 mg/L (At lower acidic pH)
TH    Have a low potential for causing hemolysis.
XR    PubMed: 20534628
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00080
XX
SQ    SEQUENCE  
      KEDNKVYGN- GTPSTCGTQQ PKVGSNNYGK T 
//


ID    AVR/I/SSAP404
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA 3700.W
IC    log10 CFU/ML = 8.97(0.03)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP405
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA Mu3
IC    log10 CFU/ML = 9.40(0.09)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP406
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA Mu50d
IC    log10 CFU/ML = 6.15(0.13)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP407
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA 3759.V
IC    log10 CFU/ML = 9.80(0.02)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP408
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 3700.W
IC    log10 CFU/ML = 9.51(0.19)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP409
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 3759.V 
IC    log10 CFU/ML = 9.90(0.02)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP410
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA 5827
IC    log10 CFU/ML = 8.67(0.44)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP411
ET    Non-clinical
PN    Ranalexin 
PL    20 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Rana catesbeiana
TX    Animalia (Frog)
VL    Experimentally validated
XX
TO    VISA 5836
IC    log10 CFU/ML = 8.72(0.16)
TH    Ranalexin caused hemolysis and toxicity to Vero cells at concentrations =>50 mg/L, but combining it with lysostaphin did not increase toxicity beyond that of ranalexin alone, with toxic concentrations exceeding those needed for antibacterial activity in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: P39084
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      FLGGLIKIVP AMICAVTKKC 
//


ID    AVR/I/SSAP412
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 5827
IC    log10 CFU/ML = 9.85(0.06)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP413
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA 5836
IC    log10 CFU/ML = 9.65(0.07)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP414
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA Mu3
IC    log10 CFU/ML = 9.64(0.04)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP415
ET    Non-clinical
PN    Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus simulans
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA Mu50
IC    log10 CFU/ML = 8.48(0.92)
TH    Lysostaphin alone showed no haemolysis or effect on Vero cell viability, and when combined with ranalexin, did not increase toxicity beyond ranalexin alone, with toxic concentrations for erythrocytes and Vero cells exceeding those needed for antibacterial efficacy in human serum.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP416
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin found in epithelial cells and neutrophils
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    ATCC 700699 (VISA)
IC    MIC = 64 microM
TH    Non-specific cytotoxicities (e.g., leukocyte, T-cell, and red blood cell viability).
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP417
ET    Non-clinical
PN    LL-37
PL    37 [Note: any special compound, if present in sequence, is not considered in length]
SR    cathelicidin found in epithelial cells and neutrophils
SO    Homo sapiens
TX    Animalia (Human)
VL    Experimentally validated
XX
TO    BR-VRSA (VRSA)
IC    MIC = 64 microM
TH    Non-specific cytotoxicities (e.g., leukocyte, T-cell, and red blood cell viability).
XR    PubMed: 30120393
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2K6O_A
XR    UniProt: Q1KLX1
XR    UniProt: P49913
XR    DrugBank: DB16532
XX
SQ    SEQUENCE  
      LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 
//


ID    AVR/I/SSAP418
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-1
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP419
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-3
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP420
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-4
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP421
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-12
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP422
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-14
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP423
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-17
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP424
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-18
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP425
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-19
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP426
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-21
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP427
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-22
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP428
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-23
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP429
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-24
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP430
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-26
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP431
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-27
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP432
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-39
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP433
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-49
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP434
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-51
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP435
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-52
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP436
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-54
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP437
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-56
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP438
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-63
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP439
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-65
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP440
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-68
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP441
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-73
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP442
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-74
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP443
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-76
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP444
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-118
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP445
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-126
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP446
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-272
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP447
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-283
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP448
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-402
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP449
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-403
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP450
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VISA NRS-404
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP451
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-1
IC    MIC = 2 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP452
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-2
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP453
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-3a
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP454
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-3b
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP455
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-4
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP456
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-5
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP457
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-6
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP458
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-7
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP459
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-8
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP460
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-9
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP461
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-10
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP462
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-11a
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP463
ET    Non-clinical
PN    LTX-109
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA VRS-11b
IC    MIC = 4 microG/ML
TH    Non-hemolytic.
XR    PubMed: 22585222
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB12711
XX
SQ    SEQUENCE  
      Gly-Gly-Gl u-Phe-Ile- Lys-Arg-Il e-Lys-Ile- Arg-Gly-Gl y 
      
//


ID    AVR/I/SSAP464
ET    Non-clinical
PN    Gramicidin
PL    16 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Soil bacterium Bacillus brevis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC = Not available
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00027
XX
SQ    SEQUENCE  
      VGALAVVVWL WLWLWG 
//


ID    AVR/I/SSAP465
ET    Non-clinical
PN    Polymyxin B
PL    18 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 10.39 microG/ML
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00781
XX
SQ    SEQUENCE  
      D-Leu-D-Le u-D-Thr-D- Pro-D-Leu- D-Val-D-Va l-D-Asp-D- Glu-D-Ile- 
      D-Asn-D-Le u-D-Ala-D- Ala-D-Ala- D-Trp-D-Ph e-D-Thr 
//


ID    AVR/I/SSAP466
ET    Non-clinical
PN    Colistin
PL    30 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus polymyxa
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC = Not available
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB00803
XX
SQ    SEQUENCE  
      D-Phe-D-Le u-D-Thr-D- Ser-D-Glu- D-Gln-L-Pr o-D-Val-D- Val-D-Leu- 
      D-Pro-D-Tr p-D-Leu-D- Lys-D-Asn- D-Ala-D-Al a-D-Ala-D- Gly-D-Ser- 
      D-Ser-D-Al a-D-Ala-D- Ala-D-Arg- D-Ser-D-Le u-D-Thr-D- Leu-D-Thr 
      
//


ID    AVR/I/SSAP467
ET    Non-clinical
PN    Bacitractin A
PL    17 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus licheniformis and Bacillus subtilis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC = 5.34 microG/ML
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      L-Asn-D-As n-D-Ala-L- Ser-D-Asn- L-Gln-D-Va l-D-Pro-D- Arg-D-Pro- 
      D-Tyr-D-Th r-D-Phe-L- Thr-D-Pro- L-Thr-D-Th r 
//


ID    AVR/I/SSAP468
ET    Non-clinical
PN    Nisin
PL    27 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Lactococcus lactis
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA
IC    MIC = Not available
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      I-Dhb-A-I- Dhb-I-A-Ab u-P-G-A-K- Abu-G-A-L- M-G-A-N-M- K-Abu-A-Ab 
      u-A-H-A-S- I-H-V-Dha- K 
//


ID    AVR/I/SSAP469
ET    Non-clinical
PN    Hominicin
PL    15 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Staphylococcus hominis MBBL 2-9
TX    Bacteria
VL    Experimentally validated
XX
TO    VISA-CCARM 3501
IC    MIC = 3.82 microG/ML
TH    Not available
XR    PubMed: 20654578
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      DmIle-Dhb- Pro-Ala-Dh b-Pro-Phe- Dhb-Pro-Al a-Ile-Thr- Glu-Ile-Dh 
      b-Ala-Ala- Val-Ile-Al a-Dmp 
//


ID    AVR/I/SSAP470
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA 3700.W
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP471
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA 3759.V
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP472
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA 5827
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP473
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA 5836
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP474
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA Mu3
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP475
ET    Non-clinical
PN    Ranalexin + Lysostaphin
PL    13 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Conjugate Synthetic Petide
TX    Not available
VL    Experimentally validated
XX
TO    VISA Mu50
IC    MIC = NIL
TH    Ranalexin alone caused hemolysis and toxicity to Vero cells at concentrations => 50 mg/L, whereas lysostaphin alone showed no hemolysis or toxicity. The combination of ranalexin and lysostaphin was no more toxic than ranalexin alone and demonstrated non-toxicity and minimal hemolytic activity at antibacterial concentrations.
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Not availa ble 
//


ID    AVR/I/SSAP476
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA01
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP477
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA02
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP478
ET    Non-clinical
PN    P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA03
IC    MIC = 64 microG/ML
TH    P-113 exhibited increased toxicity at concentrations greater than 25 microG/mL, causing 10-20% cell death and hemolysis.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: DB06763
XX
SQ    SEQUENCE  
      Ac- A K R  His His G  Y K R K F  His -NH2 
//


ID    AVR/I/SSAP479
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA01
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP480
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA02
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP481
ET    Non-clinical
PN    Phe-P-113
PL    12 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA03
IC    MIC = 64 microG/ML
TH    Phe-P-113 exhibited low toxicity and hemolytic activity. It caused minimal cell death and hemolysis, indicating a favorable safety profile compared to other peptides with bulkier hydrophobic side chains.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Phe Phe G  Y K R K F  Phe -NH2 
//


ID    AVR/I/SSAP482
ET    Non-clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA01
IC    MIC = 16 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP483
ET    Non-clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA02
IC    MIC = 16 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP484
ET    Non-clinical
PN    beta-(4, 4'-biphenyl)alanine (Bip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA03
IC    MIC = 8 microG/ML
TH    At concentrations higher than 25 microG/mL, Bip-P-113 caused increased toxicity, 10-20% cell death and hemolysis. However, in an in vivo endotoxemia mouse model, no adverse effects were observed at a dose of 10 mg/kg (0.2 mg/mouse).
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Bip Bip G  Y K R K F  Bip -NH2 
//


ID    AVR/I/SSAP485
ET    Non-clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA01
IC    MIC = 32 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP486
ET    Non-clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA02
IC    MIC = 32 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP487
ET    Non-clinical
PN    beta-diphenylalanine (Dip-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA03
IC    MIC = 32 microG/ML
TH    Dip-P-113 with bulky hydrophobic side chains caused 10-20% cell death and hemolysis at concentrations above 25microg/mL, but no adverse effects were observed in an in vivo endotoxemia mouse model treated with 10 mg/kg of Dip-P-113.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Dip Dip G  Y K R K F  Dip -NH2 
//


ID    AVR/I/SSAP488
ET    Non-clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA01
IC    MIC = 32 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP489
ET    Non-clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA02
IC    MIC = 32 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP490
ET    Non-clinical
PN    beta-naphthylalanine (Nal-P-113)
PL    9 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Synthetic peptide
TX    Not available
VL    Experimentally validated
XX
TO    VRSA03
IC    MIC = 32 microG/ML
TH    Nal-P-113, a peptide with bulky hydrophobic side chains, exhibited increased cell toxicity and hemolytic activity at higher concentrations (> 25 microG/mL), causing 10-20% cell death and hemolysis. This was in comparison to controls, indicating a potential concern for toxicity at elevated doses.
XR    PubMed: 32605123
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Ac- A K R  Nal Nal G  Y K R K F  Nal -NH2 
//


ID    AVR/I/SSAP491
ET    Non-clinical
PN    P138C
PL    14 [Note: any special compound, if present in sequence, is not considered in length]
SR    Not available
SO    Bacillus subtilis CSB138
TX    Bacteria
VL    Experimentally validated
XX
TO    VRSA
IC    MIC = 20 microG/ML 
TH    Not available
XR    PubMed: 28581021
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: Not available 
XR    UniProt: Not available
XR    DrugBank: Not available
XX
SQ    SEQUENCE  
      Gly-Leu-Gl u-Glu-Thr- Val-Tyr-Il e-Tyr-Gly- Ala-Asn-Me t-X-Ser 
      
//


